SUBSCRIBE TO OUR RSS
INITIAL PUBLIC OFFERINGS
An Open Window
Life Sciences companies that have gone public since August 2009.
The Burrill Report
April 08, 2010
[Please login to post comments]
New Hope for Brain Cancer
Anti-psychotic drugs show tumor-killing activity in glioblastoma.
Evidence Lacking on Value-based Purchasing in Healthcare
New study says government needs to create a national strategy to drive improvement.
AstraZeneca Partners with Korean Health Institute
Pharma will support 12 early-stage oncology research projects.
Venter Launches Human Longevity with $70M
Startup will use genomic sequencing to find ways to extend lifespan.
Expanding Access to Experimental ALS Drugs
Podcast: March 10, 2014
Study Casts Doubt on Benefits of the Medical Home
One long-running program led to little improvement in quality and no reduction in use of services or total costs.
Celgene Taps Abide Therapeutics for Enzyme Targeting Technology
Biotech will get $50 million, backers have potential exit.
Biotech Continues Hot Streak in U.S. Markets
Follow-on offerings top $1.7 billion in February; IPOs near $1 billion.
FDA Approves AstraZeneca Therapy for Rare Disease
Despite approval, agency plans to closely monitor therapy’s impact on patients with post-marketing studies.
A Transplant Bank Flush
Podcast: March 3, 2014
Tweets from @burrillreport/biobuzz
Copyright 2014 Burrill & Company.
FACEBOOK AND TWITTER